High Calprotectin but No Symptoms: What It Means

A high faecal calprotectin while you feel fine usually means exactly what it says: there are neutrophils in your bowel lining that you cannot feel. The test is not measuring your symptoms, and it was never designed to. It is measuring a protein that white blood cells dump into the gut when they cross into inflamed tissue, and those cells can be busy for weeks before anything reaches your awareness. Whether any tracker can see a flare coming is its own question, covered in can a symptom tracker predict a flare.

That is the most common explanation, and it is the reason modern guidelines treat a raised result in someone who feels well as a signal worth chasing rather than a curiosity. But it is not the only explanation. Painkillers you bought yourself, acid-reducing tablets, an infection you shrugged off, a polyp, a change of laboratory, or simply which bowel movement you happened to sample can all push the number up without your disease doing anything at all.

This guide is about the specific situation of a high number with a quiet body: what the value means, what it does not mean, why a bigger number is not straightforwardly a worse flare, and what usually happens next.

The short answer: the test is measuring something you cannot feel

Calprotectin is a calcium-binding protein that makes up a large share of the cytosol of neutrophils. When neutrophils migrate into an inflamed intestinal lining, some of them break down there, and the calprotectin they release survives the journey through the gut and can be measured in a stool sample. That is the whole mechanism. It is a headcount of a particular kind of white blood cell in a particular place.

Symptoms are generated by an almost entirely different set of things: how much of the bowel is involved, whereabouts it sits, how much water and bile acid reach the colon, how fast things move, how sensitive your gut nerves are, and whether the rectum is inflamed enough to trigger urgency. None of those is a direct function of the neutrophil count. So the two readings can drift apart, and they do so constantly.

Guidelines have caught up with this. The American Gastroenterological Association's Crohn's disease guideline suggests, for people in symptomatic remission, a biomarker-and-symptom-based monitoring strategy over symptoms alone, and states that a faecal calprotectin below 150 micrograms per gram with a normal CRP rules out active inflammation, while elevated biomarkers in that setting merit confirmation with endoscopy before treatment adjustment (Ananthakrishnan 2023). The companion ulcerative colitis guideline makes the parallel recommendation and adds that people in symptomatic remission with raised biomarkers should have endoscopic assessment to inform treatment decisions (Singh 2023).

That is the honest answer to "my number is high but I feel fine": it is taken seriously, it is not acted on blindly, and the next step is usually to look rather than to prescribe.

It is also worth knowing that normalising calprotectin is now a formal treatment target rather than just a monitoring tool. The STRIDE-II consensus of the International Organization for the Study of IBD, built from a systematic review of 435 included papers and two voting rounds among 89 members, set symptomatic relief and normalisation of serum and faecal markers as short-term targets, with clinical remission and endoscopic healing as the long-term ones (Turner 2021). Under that framework, a raised calprotectin in a person who feels well is a target that has not been met, not a false alarm.

Why symptoms and inflammation come apart so often

Both directions of mismatch are well documented, and neither is rare.

Inflammation without symptoms. This is the one you are reading about. It is the reason biomarker monitoring exists at all: if symptoms captured inflammation faithfully, nobody would need a stool test.

Symptoms without inflammation. The mirror image is just as common and just as confusing. In a six-year follow-up study of people with IBD in secondary care, only 33 of 125 people with data at all three time points never reported IBS-type symptoms, and 12% had persistent IBS-type symptoms throughout, while such symptoms were not associated with an increased likelihood of needing steroids, escalation, hospitalisation or resection (Fairbrass 2022). A 12-month study in the same programme found 35% of 206 people in clinical remission reported IBS-type symptoms at one or more points, and that the symptoms fluctuated in most of them (Barberio 2024). So a lot of what people feel between appointments is real but is not a measure of inflammation.

Put those together and you get the core problem: neither reading can stand in for the other, and a person who feels fine has no reliable internal sense of whether their lining is healing. If you have Crohn's, our guide to telling whether you are actually in a flare covers the other half of this problem, the look-alikes that produce flare-shaped symptoms without inflammation. If you have ulcerative colitis, how to know when your UC is flaring goes through the self-scoring side in more detail, including the first-morning sampling rule.

The clinical scores have the same blind spot. The Harvey-Bradshaw Index can be high in someone with a quiet gut and low in someone with ulcers, which we walk through in what a Harvey-Bradshaw score actually tells you. Calprotectin exists precisely because symptom scores were not enough.

How accurate is calprotectin, honestly?

Good at catching inflammation, less good at ruling other things out. In a meta-analysis of 19 studies and 2,499 people with symptoms consistent with active IBD, using endoscopy as the reference standard, faecal calprotectin had a pooled sensitivity of 0.88 and a specificity of 0.73. CRP was far less sensitive at 0.49 but more specific at 0.92, and calprotectin was more sensitive in ulcerative colitis than in Crohn's disease (Mosli 2015).

Note what that population was: people with symptoms. The accuracy figures that get quoted most often were not measured in people who feel fine, which is one reason the guidelines ask for confirmation rather than treating the number as settled.

A frequently cited study that put endoscopy and stool samples side by side found median calprotectin of 175 micrograms per gram in Crohn's disease, 465 in ulcerative colitis and 54 in people with IBS. A cutoff of 250 indicated large ulcers in Crohn's with a sensitivity of 60.4% and specificity of 79.5%, while levels at or below 250 predicted endoscopic remission with 94.1% sensitivity but only 62.2% specificity. Crucially, calprotectin correlated with symptom scores in ulcerative colitis but not in Crohn's disease (D'Haens 2012).

That last finding is the statistical version of the thing you are living. In Crohn's disease, the link between how you feel and what the lining looks like was not detectable in that dataset at all.

Does a bigger number mean a worse flare?

Up to a point, and that point arrives earlier than most people assume.

In a prospective study of 228 people with ulcerative colitis and 52 healthy controls, calprotectin correlated with endoscopic activity better than the clinical score, CRP, platelets, haemoglobin or white cell count, with a Spearman coefficient of 0.821. It was the only marker that discriminated between every grade of endoscopic activity, and the medians ran as follows (Schoepfer 2013):

Read the bottom row again. The median for the most severe endoscopic grade in that study was 611 micrograms per gram. The scale that has actually been calibrated against what an endoscopist sees runs from the tens into the high hundreds.

In Crohn's disease the picture is similar in shape. In 136 people scored with the Simple Endoscopic Score for Crohn's Disease, calprotectin correlated with the endoscopic score at R = 0.676, better than CRP at 0.458 and better than the Harvey-Bradshaw Index at 0.385, with a median calprotectin of 301 micrograms per gram across the cohort (Schaffer 2014).

A frequent piece of folk wisdom in r/CrohnsDisease puts it well: past a certain level it is just high, and 6,000 does not mean double the inflammation of 3,000. One of the most upvoted replies in a thread from someone with a result of 6,130 who felt largely fine made exactly that point, alongside the reminder that it is a point-in-time measurement and the trend matters more (r/CrohnsDisease thread). That framing matches the published data better than the threshold ladders you will find on most health sites.

Why your 137 is "slightly elevated" and someone else's 800 is not a crisis

Because the numbers that carry clinical meaning are far lower than the ones people post online, and because the same value means different things in different situations.

The most-used lines, and where each comes from:

Notice what is missing from that table: any band called "significant inflammation" starting at 500, and any published cutoff above 250 for routine use. The tidy five-rung ladders that dominate search results for this question generally do not cite a source for their rungs. We checked the page currently ranking first for "high calprotectin but no symptoms" and none of its thresholds, including "over 500, significant inflammation", carried an in-text citation to a named study or guideline.

So when a gastroenterologist calls 137 slightly elevated, they are reading it against a line at 115 or 150, not against the 6,000 somebody posted in a support group. In a thread asking what calprotectin level prompted a colonoscopy, the top reply to someone with exactly that experience made the same point plainly, while several people reported being diagnosed with significant Crohn's at values in the low hundreds (r/CrohnsDisease thread).

Things that raise calprotectin that are not your IBD

This is the part most articles skate over, and it matters enormously when you feel fine.

Medicines you may not have mentioned. In 590 people with a completely normal colonoscopy, 36% had a calprotectin above 50 micrograms per gram. In a logistic regression, age, proton pump inhibitor use (adjusted odds ratio 3.84), non-steroidal anti-inflammatory drugs (2.41) and aspirin (2.93) were all independently associated with a raised result (Lundgren 2019). NSAIDs in particular have a long history here: in the study that first proposed calprotectin as a test for NSAID enteropathy, 44% of 312 people taking NSAIDs had evidence of small bowel inflammation, and a fifth of those had levels comparable to those previously reported in IBD (Tibble 1999). That population was people with rheumatoid arthritis, osteoarthritis and other conditions, not people with IBD, but the mechanism travels.

Being older, heavier or less active. In 320 people aged 50 to 70 at average colorectal cancer risk, faecal calprotectin rose with increasing age, obesity and physical inactivity, and fell with higher fibre and vegetable intake (Poullis 2004). These were general-population adults without IBD. The effect sizes are small, but they are one reason a mildly raised value in an older person is read differently.

Infections. A gut infection recruits neutrophils just as inflammation does, and the test cannot tell the difference. This is not a reason to assume an infection, but it is a reason your team may send stool cultures and a C. difficile test alongside a repeat calprotectin, particularly after antibiotics, travel or a household bug.

Polyps and cancer. Lower gastrointestinal neoplasia raises calprotectin too, which is part of why an unexplained high result in someone over 50 or with a family history tends to be investigated rather than watched.

Bleeding from below. People often wonder whether haemorrhoids explain the number. Calprotectin comes from neutrophils, not red cells, so haemorrhoids are not a recognised cause of a markedly raised result and none of the guidelines above list them. Mention any anal bleeding anyway, because new or increasing blood always changes the assessment and should be discussed with a doctor promptly.

Can calprotectin be normal while Crohn's is active?

Yes, and this is the most under-covered part of the question. Calprotectin is a much better marker of colonic inflammation than of small bowel inflammation.

A meta-analysis of seven studies and 463 people compared calprotectin with capsule endoscopy for small bowel Crohn's disease. At a cutoff of 50 micrograms per gram, sensitivity was 0.83 but specificity only 0.53; at 200, sensitivity fell to 0.42 while specificity rose to 0.94 (Kopylov 2016). In other words, a value above 200 makes small bowel inflammation likely, but a value below 200 rules very little out.

A larger multicentre retrospective study of 333 people who had capsule endoscopy and calprotectin within three months found the correlation between calprotectin and the Lewis score was weak overall, at a Spearman coefficient of 0.232. Testing a cutoff for clinically significant small bowel inflammation gave an optimum of 76 micrograms per gram with a sensitivity of just 0.59 and specificity of 0.41, and the authors concluded that calprotectin does not appear to be a reliable biomarker for significant small bowel inflammation (Koulaouzidis 2016).

A post-hoc analysis of five prospective studies, covering 214 adults with Crohn's who had both calprotectin and small bowel capsule endoscopy, explained part of why. For the same amount of inflammation on capsule, calprotectin rose steadily the further down the gut the inflammation sat: a median of 63 micrograms per gram for proximal small bowel involvement, 190 for distal small bowel, and 542 once the colon was involved (Ukashi 2025).

So the practical translation is: a normal calprotectin is most reassuring in colonic disease and least reassuring in upper small bowel disease. If you have jejunal or proximal ileal Crohn's and a normal number, that is not the same evidence of quiet disease as it would be in colitis.

The sample itself: the ways one number goes wrong

Before anyone concludes anything from a surprising result, it is worth knowing how much of the variation comes from the stool rather than the bowel.

In a prospective study, 18 people with active ulcerative colitis collected two samples at every bowel movement over two days, producing 287 samples. The intraclass correlation between paired samples from the same bowel movement was 0.79, which is decent. But the median within-person coefficient of variation across samples collected during the same day was 52%, with a range from 4% to 178%. Calprotectin rose with the time elapsed since the previous bowel movement, which is why the authors recommended analysing the first bowel movement of the morning. Samples stored at room temperature were stable for three days but had fallen by a mean of 28% at seven days (Lasson 2015).

Extraction method adds another layer. A newer extraction device validated in 135 people with IBD agreed closely with conventional manual extraction, with a slope of 1.01 and Spearman correlation of 0.96 (Kristensen 2015), which is reassuring for that device. The automated assay verification mentioned earlier found agreement held below 800 micrograms per gram and in Bristol types 2 to 6 (Wyness 2021). Very loose or very formed samples, or samples full of undigested material, are where the pre-analytical assumptions start to strain.

A review of faecal biomarkers written for clinicians puts the same point plainly: suggested cutoffs for endoscopically active disease range from 50 to 280 micrograms per gram across studies, there is a false positive rate and there is intra-individual variability, and results must always be interpreted in clinical context, with endoscopy remaining the reference standard (Wright 2016).

High calprotectin with a clear colonoscopy

This combination distresses people more than almost any other, and the best available data are more reassuring than the internet suggests.

A Swedish study looked at 1,263 people referred for colonoscopy who provided a calprotectin sample the day before bowel preparation, and then reviewed the medical charts of the 585 whose colonoscopy was normal, over a three-year follow-up. Thirty-four per cent of those with a normal colonoscopy had a calprotectin above 50 micrograms per gram. Those people were somewhat more likely to receive an upper gastrointestinal diagnosis during follow-up (9.9% versus 4.7%), but the diagnoses were mainly benign, such as gastritis, and after adjusting for age, sex, NSAID use and proton pump inhibitor use the difference was no longer significant. There was no difference in new lower gastrointestinal diagnoses or in cardiovascular disease or death (Hovstadius 2021).

The authors' conclusion is worth quoting in substance: in people with a normal colonoscopy, a simultaneously raised calprotectin was not associated with an increased risk of significant gut disease over three years. Note the median age of 64 and the fact that these were people referred for colonoscopy for various reasons, not an established-IBD cohort.

For someone with known Crohn's, though, there is a second reading of "clear colonoscopy" that matters: a standard ileocolonoscopy reaches the colon and the last stretch of terminal ileum, and no further. If your calprotectin is high and the scope was clean, the part of the bowel that has not been looked at is usually the rest of the small intestine. That is the point at which a capsule study, MR enterography or intestinal ultrasound tends to come up. Our post on what a normal colonoscopy does and does not rule out goes through that boundary in more detail, and if a repeat scope is on the cards, colonoscopy prep with Crohn's covers the parts of the prep that are genuinely different when you have Crohn's.

Intestinal ultrasound is worth knowing about here because it is noninvasive and needs no preparation or sedation. A prospective multicentre study across 49 German, Austrian and Swiss sites followed 163 people with IBD for a year with three-monthly ultrasound, and found transmural response at week 12 predicted clinical remission at week 52 with an odds ratio of 4.3 (Kucharzik 2026). A recent narrative review is candid about the limits: there is still no universally accepted activity scoring system, and access, training, standardisation and reimbursement remain unmet needs (Jairath 2025). Several of that review's authors are affiliated with or funded by pharmaceutical companies developing IBD drugs, which is typical for reviews in this area; I did not read the individual disclosure statements line by line.

What the evidence says about acting on a number when you feel fine

This is where an honest article has to slow down, because the evidence supports paying attention to the number more strongly than it supports any particular response to it.

A raised result predicts trouble. In 79 people with clinically quiescent IBD followed for a year, a calprotectin above 150 micrograms per gram was associated with a twofold increase in relapse risk in Crohn's disease and a fourteen-fold increase in ulcerative colitis (Costa 2005). A systematic review restricted to prospective studies of asymptomatic people with IBD who had at least two consecutive measurements found six eligible studies: people with repeatedly raised values had a 53% to 83% probability of relapsing within two to three months, while people with repeatedly normal values had a 67% to 94% probability of staying in remission (Heida 2017).

And it predicts long-term damage, independent of symptoms. In a retrospective study of 918 people with Crohn's disease in Edinburgh, covering 4,218 patient-years, a raised calprotectin at the index visit was associated with subsequent progression, meaning a change in disease behaviour, hospitalisation or resection, independent of symptoms or disease location. Median calprotectin was 432 micrograms per gram in those who progressed versus 180 in those who did not, and a cutoff of 115 identified progression with a hazard ratio of 2.4. The authors concluded it is important to screen asymptomatic patients for mucosal inflammation (Kennedy 2019).

But the trial evidence for acting on it is narrower than it is usually made to sound. CALM randomised 244 people with early, moderate to severe Crohn's disease, all with visible ulcers and a Crohn's Disease Endoscopic Index of Severity above 6 at entry, to escalation driven by calprotectin at or above 250, CRP at or above 5 mg/L, symptoms or steroid use, versus escalation driven by symptoms alone. The tight control group did better and the trial met its primary endpoint: 46% reached mucosal healing without deep ulcers at 48 weeks versus 30%, an adjusted risk difference of 16.1% (Colombel 2017). CALM was funded by AbbVie, the manufacturer of the adalimumab used in both arms, and a follow-on economic analysis of the trial was also company-supported (Panaccione 2020).

Two things follow. First, CALM's population was people with ulcers at baseline, not people in remission who got one surprising result, so it does not directly answer the question this article is about. Second, its escalation trigger combined biomarkers with symptoms and steroid use, so it never tested a purely biomarker-driven decision.

A three-year follow-up of 122 CALM participants, representing half the original cohort, found that people in deep remission at the end of the trial had significantly fewer major adverse outcomes, defined as new fistulas, abscesses, strictures, hospitalisation or surgery, with an adjusted hazard ratio of 0.19. Importantly, that benefit held regardless of which monitoring strategy they had been in (Ungaro 2020). The reading that survives is that deep remission is what protects you, and biomarker monitoring is one of the tools that helps get you there.

The most careful summary comes from the asymptomatic-monitoring review itself, which concluded that two consecutively raised values are highly associated with relapse and warrant consideration of proactive optimisation, but that more prospective data are needed to assess whether calprotectin monitoring improves health outcomes (Heida 2017). That sentence has not been overtaken by a trial in people in remission. Anyone telling you the question is settled either way is going beyond the evidence.

What usually happens next

The sequence varies by team and by country, but the shape is fairly consistent.

1. Context first. Recent NSAIDs, aspirin, proton pump inhibitors, antibiotics, travel, a household stomach bug, a recent course of steroids, and whether you are actually taking your maintenance treatment as prescribed.
2. Repeat the test, usually in weeks rather than months. One value is noisy; two consecutive values carry far more information (Heida 2017). Same assay, same laboratory, first bowel movement of the day.
3. Bloods alongside it. CRP is much less sensitive than calprotectin but much more specific (Mosli 2015), so the pair tells you more than either alone. Full blood count and ferritin catch anaemia that symptoms hide.
4. Stool tests for infection if there is any reason to suspect one, including C. difficile after antibiotics.
5. Imaging or endoscopy if the elevation persists. For Crohn's in symptomatic remission, the AGA suggests confirming a raised biomarker endoscopically before adjusting treatment (Ananthakrishnan 2023). If the colon has recently been looked at and was clean, the small bowel is usually the next question, via capsule, MR enterography or intestinal ultrasound.
6. After surgery, the thresholds change. In the POCER cohort of 135 people, median calprotectin fell from 1,347 micrograms per gram before surgery to 166 at six months, and was 275 in those with endoscopic recurrence versus 72 in those in remission. A value above 100 detected endoscopic recurrence with 89% sensitivity and a 91% negative predictive value, meaning colonoscopy could have been avoided in 47% of patients (Wright 2015). If you have had a resection, your numbers are read against a different scale.

None of this involves deciding anything yourself. The point of knowing the sequence is to be able to ask where you are in it, which is a much better question than "is 800 bad".

A worked example: two people, one number

Both get a result of 620 micrograms per gram. Both feel fine. The reasonable next steps are not the same.

Person A has ileocolonic Crohn's, started a biologic four months ago, had a calprotectin of 2,100 before starting and 900 two months in. Their previous results all came from the same hospital laboratory. They take no painkillers. The trend is downward and steep, they are early in treatment, and a real-world paediatric cohort found calprotectin normalisation typically arrived at 12 to 19 weeks, well after clinical remission and CRP normalisation at 5 to 10 weeks (Frank 2026). A repeat in six to eight weeks and a conversation about whether the trajectory is good enough is a sensible next move.

Person B has ileal Crohn's, has been in remission for three years, had calprotectin of 60 last year and 75 the year before, and has been taking ibuprofen most days for a back problem without mentioning it. Their 620 is a genuine break in a stable pattern, but there is a plausible non-disease explanation sitting right there (Tibble 1999). The painkiller question comes first, then a repeat, and if it stays up, a look at the small bowel, because their disease location is exactly where calprotectin is least informative (Ukashi 2025).

Same number, same absence of symptoms, different histories, different next steps. That is why an isolated value cannot be interpreted from a chart on a website.

Tracking the number alongside how you feel

The single most useful thing you can bring to the appointment where this gets discussed is a list, in date order, of every calprotectin result you have had, with the laboratory or test name beside each one, and a rough note of what was going on at the time.

That turns an anxious question into an answerable one. Three results of 600, 610 and 620 over eight months is a plateau. Results of 60, 900 and 620 is something else. And 2,100 falling to 900 falling to 620 is a treatment working slowly. Your team may or may not have all three values in front of them, especially if tests were done in different places.

The same applies to symptoms. Because the two signals genuinely diverge, a symptom log is not a substitute for a stool test, but it is what makes the divergence visible. If you have logged a steady baseline for months and the number jumped, that is information. If you look back and notice you have quietly been more tired, or eating less, or waking earlier, the number may be describing something you had normalised. Clairop lets you log symptoms and meals by voice in a few seconds and turns the history into a report you can take to an appointment, which is the format that tends to survive a short consultation. Our guide to what to hand a clinician and what to leave out covers that handover properly, including why a 40-page export gets ignored.

Stress deserves a mention here too, because people reach for it as an explanation for a high number. The relationship is real but it does not work the way folk wisdom says, and the symptom-versus-calprotectin discordance under stress is covered in whether stress and anxiety can cause a Crohn's flare.

Myths about a high calprotectin

"If I feel fine, the number cannot be right." It can be, and this is the commonest presentation of exactly the problem biomarker monitoring exists to catch. Calprotectin predicted progression in Crohn's independent of symptoms across 4,218 patient-years (Kennedy 2019).

"If I feel fine, the number does not matter." The opposite error. It is the reading that has most often changed management in the studies above.

"6,000 is twice as bad as 3,000." No published severity gradient extends that far. The graded medians in the best UC dataset top out at 611 for the most severe endoscopic grade (Schoepfer 2013), and many assays and laboratories cap their reported values.

"Over 500 means significant inflammation." That band appears on several health sites without a citation. The thresholds that guidelines actually use are 150 for ruling out activity in symptomatic remission (Ananthakrishnan 2023, Singh 2023) and 250 as a trial escalation trigger (Colombel 2017).

"A normal calprotectin means my Crohn's is quiet." Much safer in colonic disease than small bowel disease. In one capsule endoscopy meta-analysis, sensitivity was only 0.42 at a 200 cutoff (Kopylov 2016).

"A clear colonoscopy means the high result was a mistake." Not necessarily a mistake, and usually not a disaster either. A third of people with entirely normal colonoscopies had raised values in one large series, without an increased rate of significant disease over three years (Hovstadius 2021).

"One number is enough to change my treatment." The AGA's Crohn's guideline says a raised biomarker in symptomatic remission merits confirmation before treatment adjustment (Ananthakrishnan 2023).

"My friend's doctor said they only worry above 50,000." Values that high are not reported by ordinary laboratories, and no guideline uses a threshold remotely close to it. If you have been told something like this, it is worth asking your team directly what threshold they use and why.

When to see a doctor promptly

A high calprotectin with no symptoms is usually a non-urgent conversation, arranged in days to weeks rather than the same afternoon. That changes if symptoms turn up. See a doctor promptly if you have:

• Blood in your stool, or new or increasing bleeding
• Unexplained weight loss
• Fever, drenching night sweats or feeling systemically unwell
• Symptoms that wake you from sleep
• Severe or worsening abdominal pain, especially with vomiting or an inability to pass wind or stool, which can indicate an obstruction
• Symptoms of anaemia such as marked breathlessness, dizziness or unusual fatigue
• New symptoms starting after the age of 50, or a family history of bowel cancer or IBD, if you have not been assessed for those
• Any sudden change after a course of antibiotics, which raises the question of C. difficile

Seek emergency care for severe abdominal pain with a distended abdomen and fever, for heavy rectal bleeding, or for signs of dehydration you cannot manage at home.

And if you have a high calprotectin, feel fine, and your appointment is months away, that is a reasonable thing to phone the IBD nurse line about. Asking whether a repeat test should be brought forward is a small, sensible request, and it is the step the guidelines point toward.

The honest bottom line

A high calprotectin with no symptoms most often means your bowel is inflamed in a way your nervous system has not reported, and that is a finding worth acting on. The evidence that this predicts relapse and long-term damage is solid and comes from several independent cohorts. The evidence about what exactly to do next is thinner: the main trial supporting biomarker-driven escalation enrolled people with visible ulcers, was funded by the maker of the drug used, and combined biomarkers with symptoms in its escalation rule.

So the reasonable position is the one the guidelines take. Do not dismiss the result because you feel well. Do not escalate on a single number either. Look at what else could explain it, repeat it on the same assay, and if it stays up, look at the bowel rather than guess.

And resist the urge to compare your number with the ones people post in forums. The thousands that turn up in those threads are real values, but they sit far above the range anyone has calibrated against what an endoscopist can see, and what matters for you is your own trend, your own disease location, and your own list of medicines.